As per MRFR analysis, the South Korea Liquid Biopsy Market Size was estimated at 164.68 (USD Million) in 2023.The South Korea Liquid Biopsy Market Industry is expected to grow from 182.0(USD Million) in 2024 to 546.0 (USD Million) by 2035. The South Korea Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035)
The South Korea Liquid Biopsy Market is experiencing several notable trends propelled by advancements in technology and increasing awareness of precision medicine. One key driver is the growing demand for non-invasive diagnostic methods, which are seen as less risky and more patient-friendly compared to traditional biopsies. This shift is fostering innovation in liquid biopsy technologies, including the development of advanced biomarker detection techniques, particularly for cancer diagnostics.
The government of South Korea is actively supporting research and development in this field, which encourages local companies to enhance their capabilities and foster competitive products.Another trend is the rise in collaboration between academic institutions and biotechnology companies, aiming to accelerate the development of liquid biopsy applications. This collaboration is vital as South Korea is known for its strong educational institutions and research capabilities, facilitating a steady stream of innovation. The increasing prevalence of cancer in the country further emphasizes the need for efficient diagnostic tools, driving investments in liquid biopsy technologies.
Significant opportunities are also emerging in integrating liquid biopsy results with other data sources, such as genomics and patient health records, to provide more comprehensive insights.Additionally, as the healthcare system in South Korea moves towards value-based care, liquid biopsies are becoming a crucial element in patient management. The focus on personalized medicine presents a viable pathway for growth in this market, allowing companies to develop more targeted therapies based on individual patient tumor profiles. Overall, the South Korea Liquid Biopsy Market is poised for growth driven by technological advancements and supportive policies that foster collaboration and innovation.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Increasing Incidence of Cancer in South Korea
The rising incidence of cancer in South Korea is one of the primary drivers boosting the South Korea Liquid Biopsy Market Industry. According to the South Korean National Cancer Center, cancer cases have increased significantly, with estimates showing approximately 240,000 new cancer cases reported annually. This rate signifies a robust demand for innovative diagnostic solutions, as traditional biopsy methods involve invasive procedures and are not always timely.In contrast, liquid biopsy offers a less invasive, quicker assessment and monitoring of tumor dynamics. Organizations like the Korean Society of Medical Oncology are pushing for research and development in this area, advocating for the integration of liquid biopsy technologies to improve patient outcomes. With a formidable population base exhibiting such increasing rates of oncological diagnoses, the market for liquid biopsy in South Korea is positioned for substantial growth in the coming years.
Advancements in Molecular Diagnostics
Another prominent driver for the South Korea Liquid Biopsy Market Industry is the continuous advancements in molecular diagnostics, which are improving the accuracy and efficiency of cancer detection and monitoring. Innovations in technologies such as next-generation sequencing and digital PCR have enhanced the capabilities of liquid biopsy techniques. South Korean institutions, including the Korea Advanced Institute of Science and Technology (KAIST), are at the forefront of research integration, enabling state-of-the-art advancements in this sector.As the country integrates more robust technological frameworks into healthcare systems, the growing emphasis on early detection and personalized medicine increases the reliance on non-invasive testing methods like liquid biopsies. This shift not only assists in timely interventions but also signifies a transformation in cancer care practices, further propelling market growth.
Government Initiatives Supporting Cancer Research
Government initiatives aimed at bolstering cancer research and precision medicine also play a significant role in the South Korea Liquid Biopsy Market Industry's growth. In recent years, the South Korean government has launched various programs to facilitate funding and technological development, including the Korean Biobank Project, which seeks to support research linked to cancer genomics. This initiative encourages collaboration between universities and research institutions, leading to rapid advancements in liquid biopsy technologies.Increased investment in healthcare R underscores the national priority placed on improving cancer treatment outcomes, which is directly beneficial for the liquid biopsy market segment. The focus on precision medicine is expected to continue fostering innovation, allowing the industry to flourish in alignment with national health policies.
Growing Demand for Non-Invasive Testing Solutions
The growing demand for non-invasive testing solutions in diagnostics is a key factor driving the South Korea Liquid Biopsy Market Industry. Patients increasingly prefer less invasive methods that provide quicker results with minimal discomfort. The post-pandemic emphasis on patient-centric care has highlighted the limitations of traditional diagnostic approaches, particularly given the constraints faced during COVID-19. As a result, healthcare providers in South Korea are exploring alternative approaches that align with patient preferences while ensuring effective disease monitoring and management.The Korean Medical Association has noted that adopting non-invasive diagnostic technologies can increase patient adherence to testing protocols, further propelling the demand for liquid biopsies as reliable alternatives for routine cancer screening.
The South Korea Liquid Biopsy Market is becoming increasingly significant due to its various Types segment, which includes Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and other emerging components. CTCs play an essential role in cancer diagnostics and prognosis, as they provide critical information about tumor behavior and response to treatment, promoting personalized medicine approaches within oncology. Meanwhile, ctDNA has gained traction as a non-invasive biomarker for detecting genetic mutations and assessing minimal residual disease in cancer patients, highlighting its utility in monitoring treatment efficacy and disease recurrence.Extracellular Vesicles are also emerging as important mediators in cell-to-cell communication, often involved in the transfer of RNA and proteins important for cancer progression and could serve as valuable diagnostic tools. The Others category comprises various innovative biomarkers that may not yet be fully understood but hold potential for future applications in liquid biopsy technologies.
Overall, the market demonstrates substantial growth potential, driven by advancements in technology, increased research on cancer biomarkers, and rising awareness associated with early cancer detection.Moreover, the South Korean healthcare system is investing heavily in precision medicine initiatives, which further enhances the relevance of these Types in forming a comprehensive understanding of cancer pathology. The increasing prevalence of cancer in the region, alongside a shift toward minimally invasive diagnostic methods, indicates that the demand for these various Types will continue to see an upward trend, ultimately augmenting their significance in the South Korea Liquid Biopsy Market
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The South Korea Liquid Biopsy Market is gaining traction due to its crucial applications in areas like Cancer Therapeutic Applications and Reproductive Health, among others. The Cancer Therapeutic Application is particularly significant as it offers non-invasive methods to monitor tumor progression and treatment response, thus playing a vital role in personalizing cancer care. This is in line with initiatives by the South Korean government in promoting advanced healthcare technologies, paving the way for improved patient outcomes. In Reproductive Health, liquid biopsy provides essential insights into genetic conditions, empowering couples to make informed decisions regarding family planning.The increasing prevalence of infertility issues in South Korea propels the demand for innovative reproductive technologies, highlighting the importance of these applications in a rapidly evolving healthcare landscape. Moreover, other emerging areas continue to expand, reflecting a growing awareness of liquid biopsy's capabilities in various medical fields. Overall, these applications collectively contribute to the expansion of the South Korea Liquid Biopsy Market, driven by advancements in genomic technologies and increasing healthcare investments in the region.
The South Korea Liquid Biopsy Market, particularly within the Sample segment, has shown promising growth due to rising clinical applications and advancements in technology. The Blood Sample approach is significant as it provides a non-invasive method to detect various cancers early, improving patient outcomes while being favored due to its ease of collection and high sensitivity. Urine Samples are also gaining traction as they offer a convenient alternative, particularly for screening urinary tract cancers, thus enhancing patient compliance in diagnostic procedures.Other Sample methods are emerging, contributing to the diverse diagnostic capabilities of liquid biopsies. The growth in this segment can be attributed to increasing awareness about cancer screening and advancements in molecular biology, which are driving innovations in testing methods. Notably, South Korea's robust healthcare infrastructure and emphasis on research and development in biotechnology support the growth of the South Korea Liquid Biopsy Market, reinforcing its position as a critical area in early disease detection and personalized medicine.
South Korea Liquid Biopsy Market Key Players and Competitive Insights
The South Korea Liquid Biopsy Market exhibits a dynamic and rapidly evolving competitive landscape driven by advances in molecular diagnostics and the growing demand for non-invasive cancer screening methods. The innovation in technologies related to liquid biopsies, which allow for the detection of cancer-related biomarkers in blood samples, has spurred interest among healthcare providers, researchers, and biotechnology firms in the region. As healthcare systems increasingly prioritize personalized medicine and early detection of diseases, the competition among key players intensifies.
This competitive environment is characterized by strategic collaborations, product launches, and ongoing research aimed at identifying novel biomarkers, ultimately enhancing diagnostic accuracy and treatment efficacy. The market players are also focusing on regulatory compliance and reimbursement strategies to ensure broader adoption of liquid biopsy tests in clinical practice.Natera holds a prominent position in the South Korea Liquid Biopsy Market due to its innovative approaches genetic testing and disease monitoring. The company is particularly recognized for its advanced cell-free DNA (cfDNA) technology, which enables the identification of cancerous mutations and tracking of minimal residual disease. Natera's strengths lie in its robust pipeline of liquid biopsy products that cater to various cancers, such as breast and colorectal cancers, thus appealing to a wide range of healthcare professionals.
The company's emphasis on clinical studies further enhances its credibility in the market, allowing it to build strong relationships with key opinion leaders in oncology. Additionally, Natera’s effective marketing strategies and collaborations with local hospitals and research institutions contribute to its prominent market presence and recognition among healthcare providers.Cynvenio Biosystems is another key player in the South Korea Liquid Biopsy Market, focusing on the development of its patented technology for analyzing circulating tumor cells (CTCs) found in blood samples. The company enhances its market presence through key products like its CYNvenio CTC technology, which aids in the real-time monitoring of cancer progression and treatment response.
Cynvenio's strengths include its unique analytical platform that provides valuable insights into tumor biology, helping oncologists make informed treatment decisions. The company has pursued strategic partnerships and collaborations with leading medical institutions in South Korea, enhancing its research capabilities and market reach. Strong investment in research and development has positioned Cynvenio to stay competitive while expanding its offerings and exploring potential mergers and acquisitions to bolster its portfolio in liquid biopsy solutions, thereby increasing its footprint in the South Korean market.
Key Companies in the South Korea Liquid Biopsy Market Include
South Korea Liquid Biopsy Market Industry Developments
In recent months, the South Korea Liquid Biopsy Market has seen significant developments, particularly in the realms of technology and collaboration, emphasizing the importance of early cancer detection. Companies such as Natera and Illumina are leading advancements in next-generation sequencing technologies, accelerating the availability of liquid biopsy tests for various types of cancer. The collaboration between MD Anderson Cancer Center and South Korean research institutions is enhancing the research landscape, focusing on the validation of liquid biopsy assays. In terms of mergers and acquisitions, Bristol Myers Squibb recently acquired a stake in a local biotech firm focused on liquid biopsy innovations in January 2023, further illustrating notable strategic moves in the market.
The market valuation for companies like Guardant Health and Myriad Genetics has also seen a rise due to increased healthcare investments and the growing demand for non-invasive tests, which is contributing to the overall growth of the liquid biopsy sector in South Korea. Over the past two to three years, regulatory approvals for new liquid biopsy tests have gained traction, indicating a shifting landscape toward personalized medicine and improved patient outcomes in the oncology field.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 164.68(USD Million) |
| MARKET SIZE 2024 | 182.0(USD Million) |
| MARKET SIZE 2035 | 546.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.503% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Natera, Cynvenio Biosystems, Sysmex, Illumina, BristolMyers Squibb, Myriad Genetics, Thermo Fisher Scientific, MD Anderson Cancer Center, Exact Sciences, Guardant Health, QIAGEN, Biocept, F. HoffmannLa Roche, GRAIL, Roche |
| SEGMENTS COVERED | Types, Application, Sample |
| KEY MARKET OPPORTUNITIES | Rising cancer prevalence, Increasing demand for non-invasive testing, Advancements in genomic technologies, Growing awareness of personalized medicine, Expanding research and clinical applications |
| KEY MARKET DYNAMICS | Growing demand for non-invasive testing, Increasing prevalence of cancer, Advancements in genomic technologies, Supportive government policies, Expanding R&D investments |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Liquid Biopsy Market is expected to be valued at 182.0 million USD in 2024.
The expected CAGR for the South Korea Liquid Biopsy Market from 2025 to 2035 is 10.503 percent.
By 2035, the South Korea Liquid Biopsy Market is projected to reach a value of 546.0 million USD.
Circulating Tumor Cells are valued at 50.0 million USD in the South Korea Liquid Biopsy Market in 2024.
By 2035, Circulating Tumor DNA is estimated to be valued at 210.0 million USD in the South Korea Liquid Biopsy Market.
Key players in the South Korea Liquid Biopsy Market include companies such as Natera, Illumina, and Thermo Fisher Scientific.
Extracellular Vesicles are valued at 40.0 million USD in the South Korea Liquid Biopsy Market in 2024.
The market presents growth opportunities driven by advancements in cancer detection and personalized medicine.
Challenges might include regulatory hurdles and the need for robust clinical validation across various applications.
'Others' in the South Korea Liquid Biopsy Market is projected to be valued at 22.0 million USD in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
